Prevalence of antibiotic resistance among Egyptian Salmonella typhi strains. 1996

M O Wasfy, and D A Moustafa, and A M El-Gendy, and Z S Mohran, and T F Ismail, and S H El-Etr, and B A Oyofo
Research Sciences Department, U.S. Naval Medical Research Unit No. 3, Cairo, Egypt.

This report describes the resistance of 537 Salmonella typhi isolates identified in Egypt between 1990-1994. Results indicated a high isolation rate for multiple resistant S. typhi (> 71% of isolates collected in 1992-93), particularly to the three standard drug regimens of the clinically relevant antibiotics; ampicillin, chloramphenicol and trimethoprim-sulfamethoxazole. This adds to the complexity and difficulty of treating infections caused by these organisms. Resistance of S. typhi was associated with a transferable 120 MD plasmid. The organism was sensitive to amikacin, aztreonam, cephalothin, ceftriaxone, gentamicin and nalidixic acid, suggesting the use of aztreonam and ceftriaxone as alternative therapeutic drugs for the treatment of multidrug-resistant S. typhi. These results may provide a clinically useful evaluation of the spread and acquisition of resistance among S. typhi strains in Egypt.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D004534 Egypt A country in northern Africa, bordering the Mediterranean Sea, between Libya and the Gaza Strip, and the Red Sea north of Sudan, and includes the Asian Sinai Peninsula Its capital is Cairo. Arab Republic of Egypt,United Arab Republic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D012485 Salmonella typhi A serotype of SALMONELLA ENTERICA which is the etiologic agent of TYPHOID FEVER. Salmonella enterica serovar Typhi,Salmonella typhosa
D014435 Typhoid Fever An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA. Enteric Fever,Typhus, Abdominal,Salmonella typhi Infection,Typhoid,Abdominal Typhus,Enteric Fevers,Fever, Enteric,Fever, Typhoid,Fevers, Enteric,Fevers, Typhoid,Infection, Salmonella typhi,Infections, Salmonella typhi,Salmonella typhi Infections,Typhoid Fevers,Typhoids
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D018570 Risk Assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988) Assessment, Risk,Benefit-Risk Assessment,Risk Analysis,Risk-Benefit Assessment,Health Risk Assessment,Risks and Benefits,Analysis, Risk,Assessment, Benefit-Risk,Assessment, Health Risk,Assessment, Risk-Benefit,Benefit Risk Assessment,Benefit-Risk Assessments,Benefits and Risks,Health Risk Assessments,Risk Analyses,Risk Assessment, Health,Risk Assessments,Risk Benefit Assessment,Risk-Benefit Assessments

Related Publications

M O Wasfy, and D A Moustafa, and A M El-Gendy, and Z S Mohran, and T F Ismail, and S H El-Etr, and B A Oyofo
January 1994, The Journal of antimicrobial chemotherapy,
M O Wasfy, and D A Moustafa, and A M El-Gendy, and Z S Mohran, and T F Ismail, and S H El-Etr, and B A Oyofo
January 1978, Revista latinoamericana de microbiologia,
M O Wasfy, and D A Moustafa, and A M El-Gendy, and Z S Mohran, and T F Ismail, and S H El-Etr, and B A Oyofo
April 2022, Archives of Razi Institute,
M O Wasfy, and D A Moustafa, and A M El-Gendy, and Z S Mohran, and T F Ismail, and S H El-Etr, and B A Oyofo
January 1983, Annales de microbiologie,
M O Wasfy, and D A Moustafa, and A M El-Gendy, and Z S Mohran, and T F Ismail, and S H El-Etr, and B A Oyofo
September 1990, The Journal of infectious diseases,
M O Wasfy, and D A Moustafa, and A M El-Gendy, and Z S Mohran, and T F Ismail, and S H El-Etr, and B A Oyofo
April 2024, Cureus,
M O Wasfy, and D A Moustafa, and A M El-Gendy, and Z S Mohran, and T F Ismail, and S H El-Etr, and B A Oyofo
August 2008, Journal of infection in developing countries,
M O Wasfy, and D A Moustafa, and A M El-Gendy, and Z S Mohran, and T F Ismail, and S H El-Etr, and B A Oyofo
March 1966, The Indian journal of medical research,
M O Wasfy, and D A Moustafa, and A M El-Gendy, and Z S Mohran, and T F Ismail, and S H El-Etr, and B A Oyofo
November 1991, Enfermedades infecciosas y microbiologia clinica,
M O Wasfy, and D A Moustafa, and A M El-Gendy, and Z S Mohran, and T F Ismail, and S H El-Etr, and B A Oyofo
April 2003, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!